Kirtane et al., 2021 - Google Patents
Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges aheadKirtane et al., 2021
View HTML- Document ID
- 15071032840840449775
- Author
- Kirtane K
- Elmariah H
- Chung C
- Abate-Daga D
- Publication year
- Publication venue
- Journal for immunotherapy of cancer
External Links
Snippet
While immune checkpoint inhibitors (ICIs) have ushered in major changes in standards of care for many solid tumor malignancies, primary and acquired resistance is common. Insufficient antitumor T cells, inadequate function of these cells, and impaired formation of …
- 206010028980 Neoplasm 0 title abstract description 127
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kirtane et al. | Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead | |
| Bielamowicz et al. | Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma | |
| JP7527049B2 (en) | CAR expression vector and CAR-expressing T cells | |
| Koury et al. | Immunotherapies: exploiting the immune system for cancer treatment | |
| Wedekind et al. | Pediatric cancer immunotherapy: opportunities and challenges | |
| Alnefaie et al. | Chimeric antigen receptor T-cells: an overview of concepts, applications, limitations, and proposed solutions | |
| Minutolo et al. | The emergence of universal immune receptor T cell therapy for cancer | |
| Lupo et al. | CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma | |
| Li et al. | Increasing the safety and efficacy of chimeric antigen receptor T cell therapy | |
| Qin et al. | Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells | |
| Han et al. | Antitumor effects and persistence of a novel HER2 CAR T cells directed to gastric cancer in preclinical models | |
| Yeku et al. | Adoptive T-cell therapy for solid tumors | |
| Figueroa et al. | Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy | |
| Davila et al. | Biology and clinical application of CAR T cells for B cell malignancies | |
| Wu et al. | B7H6-specific bispecific T cell engagers lead to tumor elimination and host antitumor immunity | |
| Ahmed et al. | HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors | |
| Han et al. | Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges | |
| Firor et al. | From humble beginnings to success in the clinic: Chimeric antigen receptor-modified T-cells and implications for immunotherapy | |
| JP2020517259A5 (en) | ||
| Vyas et al. | Antigen loss variants: catching hold of escaping foes | |
| Salinas et al. | Potential of glioblastoma-targeted chimeric antigen receptor (CAR) T-cell therapy | |
| Jakobsen et al. | CAR T-cell cancer therapy targeting surface cancer/testis antigens | |
| Blanco et al. | Engineering immune cells for in vivo secretion of tumor-specific T cell-redirecting bispecific antibodies | |
| Han et al. | Chimeric antigen receptor modified T-cells for cancer treatment | |
| Kandra et al. | Utility and drawbacks of chimeric antigen receptor T cell (CAR-T) therapy in lung cancer |